Sales Growth YoY (Last 12 Months): werewolftx.com (HOWL)

Public company logo of werewolftx.com (HOWL)

Risk diversification through the development of selective immunopreparations correlates with the TTM revenue growth YoY metric on the GURU.Markets chart, where the indicator level is -100.00. The environmental profile of Werewolf Therapeutics (HOWL) is limited to basic laboratory safety controls. Asset value growth is driven by the success of the PREDATOR platform in reducing therapy toxicity and the receipt of partner payments following clinical trials.

Werewolf (HOWL) Revenue Growth YoY (Last 12 Months): for the period 02/11/2024 - 11/17/2026

Werewolf Therapeutics (HOWL) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Summary company analytics:Werewolf Therapeutics
Product sample of Werewolf

A qualitative asset valuation requires an analysis of its commercial scaling dynamics. This indicator measures the change in annual revenue using a twelve-month rolling total, neutralizing seasonality and random market spikes. By analyzing the rolling year-over-year revenue growth chart, an investor determines the actual strength of the business expansion. For Werewolf Therapeutics (HOWL), this metric will become critical during the transition to the monetization of unique immunocytokines. Growth in this indicator will confirm the formation of a long-term monopolistic cash flow.

Competitors of Werewolf Therapeutics (HOWL)

Sales Growth YoY (TTM) NantKwest IBRX|IMCR - Sales Growth YoY (Last Twelve Months)|JANX (januxrx.com) - Sales Growth YoY (Last 12 Months)|Arcus Corp (RCUS) - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Revenue Growth Zymeworks Corp (ZYME)|Revenue Growth YoY (Last 12 Months) TNGX|IOVA - Revenue Growth Rate YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) IMTX (Immatics Corp)|Revenue Change YoY (Last 12 Months) XNCR|Sales Growth YoY (TTM) CMPX (Compass Therapeutics, Inc.)|Revenue Dynamics YoY (Last Twelve Months) REPL|lyell.com - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Innate Pharma S.A|Pyxis (PYXS) - Sales Growth YoY (Last Twelve Months)|Compugen Ltd - Revenue Dynamics YoY (Last Twelve Months)|IOBT (iobiotech.com) - Sales Growth YoY (TTM)|Sales Growth YoY (TTM) Sutro Biopharma Inc.|Sales Growth YoY (Last Twelve Months) MiNK Therapeutics (INKT)|IMMX: Trailing Twelve Months Sales Growth|alxoncology.com - Revenue Growth YoY (Last 12 Months)|CUE - Revenue Growth YoY (Last 12 Months)|PDSB - Sales Growth YoY (Last Twelve Months)|Annual Revenue Growth (Last Twelve Months) Sonnet BioTherapeutics Holdings SONN|MAIA: Sales Growth YoY (TTM)|LIMN - Annual Revenue Growth (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) LVTX|Sales Growth YoY (Last 12 Months) NXTC (NextCure)|Sales Growth YoY (Last Twelve Months) leaptx.com (LPTX)|INTS - Trailing Twelve Months Revenue Growth|Sales Growth YoY (TTM) SNSE (Sensei Biotherapeutics, Inc.)|Annual Revenue Growth (Last Twelve Months) Theriva Biologics, Inc. (TOVX)|GRTS: Revenue Growth YoY (Last 12 Months)|Annual Revenue Growth (Last Twelve Months) kinetabio.com KA|NEXI (neximmune.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Turnstone Biologics Corporation (TSBX)|Revenue Growth YoY (Last 12 Months) VCNX|HARP: Revenue Dynamics YoY (Last Twelve Months)